Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/182983
Title: A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib
Authors: Santangelo, Alessandra
Rossato, Marzia
Lombardi, Giuseppe
Benfatto, Salvatore
Lavezzari, Denise
De Salvo, Gian Luca
Indraccolo, Stefano
Dechecchi, Maria Cristina
Prandini, Paola
Gambari, Roberto
Scapoli, Chiara
Di Gennaro, Gianfranco
Caccese, Mario
Eoli, Marica
Rudà, Roberta
Brandes, Alba Ariela
Ibrahim, Toni
Rizzato, Simona
Lolli, Ivan
Lippi, Giuseppe
Delledonne, Massimo
Zagonel, Vittorina
Cabrini, Giulio
Keywords: CDKN1A;HIF1A;glioblastoma;miR-93-5p;regorafenib
Issue Date: 14-Jul-2020
Journal: Neuro-oncology 
Abstract: 
Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity of GBMs, we aimed to identify molecular biomarkers predictive of differential response to the drug.
URI: http://hdl.handle.net/20.500.12857/182983
DOI: 10.1093/neuonc/noaa156
Appears in Collections:Articles

Show full item record

PubMed Central
Citations

4
checked on May 2, 2021

WEB OF SCIENCETM
Citations

11
checked on Nov 24, 2021

Page view(s) 5

2
checked on Nov 29, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.